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Objectives This study reports a prospectively planned analysis of patients with acute coronary syndrome who underwent
early percutaneous coronary intervention (PCI) in the OASIS-5 (Fifth Organization to Assess Strategies in Ische-
mic Syndromes) trial.
Background In the OASIS-5 trial, fondaparinux was similar to enoxaparin for short-term efficacy, but reduced major bleeding
by one-half and 30-day mortality by 17%.
Methods The OASIS-5 trial was a double-blind, randomized comparison of fondaparinux and enoxaparin in 20,078 pa-
tients with acute coronary syndrome. A total of 12,715 patients underwent heart catheterization during the ini-
tial hospitalization, and 6,238 patients underwent PCI. In the fondaparinux group, intravenous fondaparinux was
given for PCI. In the enoxaparin group, no additional anticoagulant was given if PCI was 6 h from last subcuta-
neous dose, and additional intravenous unfractionated heparin (UFH) was given if PCI was 6 h.
Results Fondaparinux compared with enoxaparin reduced major bleeding by more than one-half (2.4% vs. 5.1%, hazard
ratio [HR] 0.46, p  0.00001) at day 9, with similar rates of ischemic events, resulting in superior net clinical
benefit (death, myocardial infarction, stroke, major bleeding: 8.2% vs. 10.4%, HR 0.78, p  0.004). Fonda-
parinux reduced major bleeding 48 h after PCI irrespective of whether PCI was performed 6 h of the last
enoxaparin dose (1.6% vs. 3.8%, HR 0.42, p  0.0001) or 6 h when UFH was given (1.3% vs. 3.4%, HR 0.39,
p  0.0001). Catheter thrombus was more common in patients receiving fondaparinux (0.9%) than enoxaparin
alone (0.4%), but was largely prevented by using UFH at the time of PCI, without any increase in bleeding.
Conclusions Upstream therapy with fondaparinux compared with upstream enoxaparin substantially reduces major bleeding
while maintaining efficacy, resulting in superior net clinical benefit. The use of standard UFH in place of fonda-
parinux at the time of PCI seems to prevent angiographic complications, including catheter thrombus, without
compromising the benefits of upstream fondaparinux. (J Am Coll Cardiol 2007;50:1742–51) © 2007 by the
American College of Cardiology Foundation
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October 30, 2007:1742–51 The OASIS-5 PCI Substudyespite advances in antithrombotic therapies and percuta-
eous coronary intervention (PCI) for the management of
atients with acute coronary syndrome (ACS), major car-
iovascular events and bleeding complications remain im-
ortant concerns. Evidence for the effectiveness of an early
nvasive management strategy in higher-risk ACS patients
as led to the increasing use of PCI worldwide (1–4). In the
.S., contemporary registry data suggest that approximately
0% of all individuals presenting with ACS presently
ndergo a PCI procedure during the initial hospitalization
5). Efforts to further improve antithrombotic therapy in
atients presenting with ACS have focused on preserving or
nhancing efficacy while reducing major bleeding compli-
ations. Major bleeding has been associated with increased
ates of ischemic events and mortality in rigorously per-
ormed observational analyses (6–8).
The OASIS-5 (Fifth Organization to Assess Strategies in
schemic Syndromes) trial showed that the synthetic factor
a inhibitor fondaparinux reduced major bleeding by 50%
nd 30-day mortality by 17% compared with enoxaparin in
ore than 20,000 patients with unstable angina or non–
T-segment elevation myocardial infarction (MI) (9). More
han 14,000 patients in the OASIS-5 trial were randomized
rom centers with on-site catheterization laboratories, and
ore than 12,000 patients underwent heart catheterization
uring the initial hospitalization (10). Here we report the
esults of a prospectively planned analysis of the efficacy and
afety of fondaparinux compared with enoxaparin in pa-
ients enrolled in the OASIS-5 trial who underwent PCI
including early PCI) during the study treatment period.
ethods
atients. The OASIS-5 trial design and rationale and the
rimary results have been previously published (9,10).
riefly, patients with unstable angina or non–ST-segment
levation MI were randomized, in a double-blind, double-
ummy fashion, to receive either subcutaneous fonda-
arinux 2.5 mg once daily or subcutaneous enoxaparin 1
g/kg twice daily (dose reduced to 1 mg/kg once daily in
atients with creatinine clearance 30 ml/min). Patients
ere eligible for inclusion in the OASIS-5 trial if they met
t least 2 of the following criteria: age 60 years, positive
ardiac biomarkers, or electrocardiographic changes com-
atible with ischemia. Key exclusion criteria were any
ontraindication to low-molecular-weight heparin, hemor-
hagic stroke within the last 12 months, an indication for
nticoagulation other than ACS, revascularization proce-
ure already performed for the qualifying event, and severe
enal insufficiency (i.e., serum creatinine 3 mg/dl or 265
mol/l). Patients could be treated with study drug for a
aximum of 8 days after randomization. However, the
edian duration of therapy in patients undergoing PCI was
nly 2.5 days. Study drug was stopped because of either
linical stabilization, a revascularization procedure, or dis-
harge home from hospital.rotocol for study drug admin-
stration in PCI patients. The
dministration of study drugs dur-
ng PCI maintained the double-
ummy, double-blind design
Fig. 1) (10). The dose of study
rug administered at PCI was
etermined by the time that had
lapsed since administration of
he last subcutaneous injection of
tudy drug, and by whether con-
urrent glycoprotein (GP) IIb/
IIa inhibitors were to be used
Fig. 1). Monitoring of the acti-
ated clotting time (ACT) dur-
ng PCI was not recommended
ecause standard doses of unfrac-
ionated heparin (UFH) were used, but the ACT could be
easured at the discretion of the investigator, particularly if
clinical need arose. Centers had the option of continuing
tudy drug after a revascularization procedure, but this was
ot mandated by the study protocol. Sheaths could be
emoved immediately after PCI if a vascular closure device
as used or a radial artery procedure was performed or 6
after the last injection of fondaparinux or enoxaparin.
Figure 1 Dosing of Study Drug in Patients Undergoing PCI
The dosing regimen for percutaneous coronary intervention (PCI) procedures in
the fondaparinux (fonda) and enoxaparin (enox) groups according to time after
last subcutaneous (sc) dose of study drug and use of glycoprotein (GP) IIb/IIIa
antagonists. All study drugs were given in a double-blind, double-dummy fash-
ion. IV  intravenous; UFH  unfractionated heparin.
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
ACT  activated clotting
time
CI  confidence interval
GP  glycoprotein
HR  hazard ratio
MI  myocardial infarction
PCI  percutaneous
coronary intervention
RR  relative risk
UFH  unfractionated
heparin
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The OASIS-5 PCI Substudy October 30, 2007:1742–51After isolated reports of catheter thrombosis in a small
umber of patients (whose treatment allocation remained
linded), a protocol amendment was instituted on June 24,
004, that detailed the correct method of administration of
ntravenous study drug and emphasized the importance of
ushing all catheters and the intravenous line to ensure that
he entire bolus of study drug (0.5-ml fondaparinux)
eached the patient. In addition, centers were reminded
hat, at the investigator’s discretion, it was permissible to
ive open-label UFH before PCI in addition to the
rotocol-mandated study drug (10). Importantly, the case
eport forms were amended to capture all cases of catheter
hrombus and to capture whether open-label UFH was
iven in the catheterization laboratory before PCI.
utcomes. The PCI analysis was a prespecified subgroup
nalysis of the OASIS-5 trial. Safety was assessed by
valuating rates of major bleeding and efficacy by evaluating
he composite of death, MI, or stroke at days 9, 30, and 180.
efinitions of these outcomes have been previously reported
9,10). Major bleeding was defined as clinically overt bleed-
ng that was either fatal, intracranial, retroperitoneal, in-
raocular, a decrease in hemoglobin of 3.0 g/dl (with each
lood transfusion unit counting for 1.0 g/dl of hemoglobin),
r requiring transfusion of 2 U of red blood cells. An
nalysis of efficacy and safety results in patients undergoing
ery early PCI (within 24 h) was also prespecified. Creatine
inase and creatine kinase-MB were measured routinely at
to 8 h and 12 to 14 h after PCI. Within 48 h after PCI,
new MI was defined by creatine kinase-MB 3 the
pper limit of normal (or increased by 50% from the
reprocedural valley level) or new ST-segment elevation or
ew Q waves (10). Threatened abrupt closure was defined as
he composite of new angiographic thrombus, major dissec-
ion, or no-reflow phenomenon. Guiding catheter-related
hrombus was reported as an adverse event in the first 4,480
CIs performed and was routinely collected in the final
,758 patients undergoing PCI after implementation of the
odification to the case report forms.
To evaluate the potential impact of additional UFH, the
ates of catheter thrombus and major bleeding were exam-
ned separately using 2 approaches. In patients randomized
o enoxaparin, the use of protocol-mandated UFH during
CI was assessed according to whether the PCI was
erformed6 h of the last enoxaparin dose (where no UFH
as given by protocol) or 6 h after the last enoxaparin
ose (where UFH was recommended). The use of addi-
ional open-label UFH immediately before PCI was evalu-
ted in both treatment groups.
tatistical analysis. An intention-to-treat approach was
sed for all analyses. All patients undergoing PCI during
he study treatment period were included. All events occur-
ing from randomization up to 9, 30, and 180 days were
ncluded in the analysis. Event rates within each group were
alculated using the Kaplan-Meier estimator. For death,
I, stroke, and bleeding, the hazard ratio (HR) and 2-sided
5% confidence interval (CI) were calculated with use of the fox proportional hazards model, with treatment effect as
he only covariate. For all other comparisons, means and
roportions were compared using the unpaired t test and
hi-square test, respectively. A chi-square test was also used
o compare the groups for major bleeding according to day
fter randomization. Separate analyses were performed com-
aring the treatment groups according to whether PCI was
erformed within 6 h of the last study drug administration
where fondaparinux was compared with enoxaparin) or more
han 6 h from the last study drug administration (where
ondaparinux was compared with the combination of
noxaparin and protocol-mandated UFH), and according to
hether open-label UFH was used. All analyses were
erformed using SAS version 9.1 (SAS Institute Inc., Cary,
orth Carolina).
esults
he disposition of patients undergoing PCI in the trial in
elation to randomized treatment and use of open-label
FH is summarized in Figure 2. A total of 14,206 patients
nrolled in the OASIS-5 trial underwent heart catheteriza-
ion, 12,715 during the study drug administration period. A
otal of 8,100 patients underwent revascularization, includ-
ng 6,238 PCIs and 1,862 coronary artery bypass grafts.
verall, 1,414 and 1,420 patients in the fondaparinux and
noxaparin groups, respectively, had early PCI within 24 h
f randomization; an additional 1,976 and 1,972 within
8 h and 1,158 and 1,162 between 48 h and 8 days.
ubcutaneous fondaparinux/placebo was given for a mean
f 2.4 (standard deviation 1.8) days before PCI and
noxaparin/placebo was given for a mean of 2.6 (standard
eviation 1.8) days before PCI.
aseline characteristics. The baseline characteristics are
ell matched between the 2 randomized treatment groups
Table 1). Overall, 98.9% of patients in the fondaparinux
roup and 98.6% in the enoxaparin group received aspirin,
1.1% and 92.3% received a thienopyridine, and 38.8% and
0.4%, respectively, received an intravenous GP IIb/IIIa
nhibitor (Table 1). Of the 8,754 lesions that were inter-
ened on, 84.4% in the fondaparinux group and 85.3% in
he enoxaparin group were treated with an intracoronary
tent, of which 23.2% versus 22.9%, respectively, were
rug-eluting stents (Table 1).
linical outcomes. In the fondaparinux group, 6.3% of
atients experienced a death, MI, or stroke by day 9,
ompared with 6.2% of patients in the enoxaparin group
HR 1.03, 95% CI 0.84 to 1.25, p  0.79) (Table 2). Each
utcome taken individually and at 30 days and 6 months
as also similar between the groups (Table 2). After PCI,
he proportion of patients requiring urgent intervention
ithin 24 h of recurrent ischemia did not differ between the
groups: 0.2% versus 0.2% at 48 h after the PCI and 0.7%
ersus 0.7% at 6 months.
Major bleeding at day 9 was significantly reduced withondaparinux compared with enoxaparin (2.4% vs. 5.1%,
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October 30, 2007:1742–51 The OASIS-5 PCI SubstudyR 0.46, p  0.00001) (Table 2). Similarly, there were
arge reductions in minor and total bleeding with fonda-
arinux (Table 2). Major bleeding was reduced with
ondaparinux as early as the same day of randomization
i.e., within hours after administration of the first dose of
tudy drug) (Table 3). Similarly, major bleeding was lower
ith fondaparinux on the first day and subsequent days after
andomization (Table 3).
In addition, fondaparinux was superior to enoxaparin in
educing major bleeding at day 9 irrespective of whether the
tudy drug was restarted after PCI (1.9% vs. 4.4%, HR 0.42,
 0.00001) or was not restarted after the procedure (3.7%
s. 6.6%, HR 0.55, p  0.00001). The study drug was
estarted after PCI in 67.4% of patients for a median of 1
ay after PCI. Overall, restarting of the study drug after
CI did not seem to increase major bleeding (3.1% study
rug restarted vs. 5.1% study drug not restarted, relative risk
RR] 0.61, p  0.0001).
The bleeding reduction with fondaparinux compared
ith enoxaparin was consistent irrespective of age or renal
unction. Major bleeding at 30 days in those 65 years old
4.1% vs. 8.0%, HR 0.49, 95% CI 0.37 to 0.66, p 
.00001) and those 65 years old (1.5% vs. 2.5%, HR 0.58,
5% CI 0.34 to 0.99, p  0.047) was significantly lower
ith fondaparinux. Similarly, major bleeding at 30 days in
atients with a glomerular filtration rate below the median
f 71 ml/min (3.9% vs. 8.0%, HR 0.47, 95% CI 0.34 to
Figure 2 Flow Diagram of Patients Undergoing PCI
The disposition of patients undergoing percutaneous coronary intervention (PCI) in
unfractionated heparin (UFH). *8 days was the maximum duration of study drug ad
amendment..66, p  0.00001) and greater than or equal to the median b2.0% vs. 3.5%, HR 0.58, 95% CI 0.39 to 0.88, p  0.01)
as also consistently reduced with fondaparinux.
Patients undergoing PCI who experienced a major bleed-
ng event during the initial hospitalization had substantially
igher rates of death (1.7% vs. 10.1%, HR 6.00, 95% CI 3.82
o 9.42, p  0.00001), MI (5.3% vs. 14.3%, HR 2.77, p 
.00001), and stroke (0.5% vs. 3.1%, HR 5.99, p  0.00001)
t 30 days and at 6 months (death: HR 4.31, p 0.00001; MI:
R 2.47, p  0.00001; stroke: HR 5.55, p  0.00001).
The net clinical composite of death, MI, stroke, or major
leeding was significantly lower with fondaparinux com-
ared with enoxaparin at day 9 (8.2% vs. 10.4%, HR 0.78,
 0.004). This net clinical benefit of fondaparinux was
reserved at longer-term follow-up at day 30 and at
months (Table 2).
utcomes in patients undergoing early PCI. In patients
ndergoing PCI within the first 24 h, death, MI, or stroke
ccurred in 5.3% in the fondaparinux group and 5.4% in the
noxaparin group (HR 0.98, 95% CI 0.71 to 1.34) (Table 3).
owever, there was a marked reduction in major bleeding
ith fondaparinux (2.3% vs. 4.9%, HR 0.48, p  0.0005)
Table 4). The net clinical outcome of death, MI, stroke, or
ajor bleeding favored fondaparinux in those undergoing
arly PCI (7.3% vs. 9.5%, HR 0.76, p  0.035) (Table 4).
ngiographic outcomes and vascular access site compli-
ations. Abrupt closure (1.5% vs. 1.1%) and threatened
brupt closure (5.3% vs. 4.7%) did not differ significantly
ASIS-5 trial in relation to randomized treatment and use of open-label
tration. Mean duration of treatment was 2.5 days. †Following protocolthe O
minisetween the fondaparinux and enoxaparin groups, respec-
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The OASIS-5 PCI Substudy October 30, 2007:1742–51ively. Overall vascular access site complications 48 h after
CI were substantially lower with fondaparinux than
noxaparin (3.2% vs. 8.1%, HR 0.40, p  0.0001), includ-
ng large hematomas (1.5% vs. 4.5%, HR 0.34, p  0.0001)
nd pseudoaneurysms (1.0% vs. 1.6%, HR 0.63, p 0.038).
atheter thrombus occurred in 1% of patients and was
bserved in both the fondaparinux and the enoxaparin
roups. Overall, it was more common in the fondaparinux
roup (0.9%) compared with those undergoing PCI with
noxaparin alone (0.4%) and with those undergoing PCI
ith UFH added to enoxaparin 6 h after the last subcuta-
eous dose (0.2%). Irrespective of randomized treatment
aseline Characteristics,oncurrent Medications, and Procedural Details
Table 1 Baseline Characteristics,Concurrent Medications, and Procedural Details
Outcome
Fondaparinux (%)
(n  3,134)
Enoxaparin (%)
(n  3,104)
Age, yrs (mean) 64.6 64.5
Female 28.3 30.9
Troponin/creatine kinase-MB  upper
limit of normal
79.0 80.3
ST-segment depression 1 mm 42.3 39.2
Transient ST-segment elevation 2 mm 3.5 3.8
Transient ST-segment elevation 1 mm 3.5 4.3
T-wave inversion (2 mm) 21.3 22.0
Prior heart failure 7.2 7.4
Prior MI 22.6 20.0
Diabetic 23.5 23.1
Prior CABG 9.0 8.4
Prior PCI 16.9 16.1
Medications after randomization
ASA 98.6 98.9
Clopidogrel 91.1 92.3
Clopidogrel 6 h before 29.1 29.7
Beta-blocker 88.1 89.5
ACE/ARB 73.7 73.8
Statin 83.7 83.6
Glycoprotein IIb/IIIa inhibitor 40.4 38.8
Procedural details
Number of lesions 4,417 4,337
Complete success 91.8 91.9
Partial success 3.1 2.8
Intracoronary stent 84.4 85.3
Drug-eluting stent 23.2 22.9
Thrombus before PCI 15.2 14.1
Access site
Femoral 87.5 88.4
Radial 12.0 11.0
Brachial 0.6 0.5
PCI location
Left main 1.0 1.5
Left anterior descending 41.5 42.0
Circumflex artery 26.4 25.9
Right coronary artery 27.7 27.1
Saphenous vein graft 3.3 3.4
values for all comparisons 0.05.
ACE  angiotensin-converting enzyme inhibitor; ARB  angiotensin receptor blocker; ASA 
cetylsalicylic acid; CABG  coronary artery bypass graft surgery; MI  myocardial infarction;
CI  percutaneous coronary intervention.roup, patients who experienced catheter-related thrombus 3ad significantly higher rates of MI (27% catheter thrombus
s. 4.2% no catheter thrombus, RR 6.51, 95% CI 3.78 to
1.20) and stroke (5.4% vs. 0.6%, RR 9.48, 95% CI 2.37 to
8.0) at 30 days. Mortality was 2.7% in those patients who
ad a catheter thrombus and 2.1% in those who did not (RR
.31, 95% CI 0.19 to 9.17).
atheter thrombus and concomitant use of UFH. EFFECT
F PROTOCOL-RECOMMENDED UFH. When PCI was per-
ormed 6 h of the last enoxaparin subcutaneous dose, the
ates of abrupt closure and threatened abrupt closure did not
iffer between the enoxaparin and fondaparinux groups
5.9% fondaparinux alone vs. 6.2% enoxaparin alone, HR
.96, 95% CI 0.73 to 1.26, p  0.78); however, there was a
arge reduction in vascular access site complications in favor
f fondaparinux (3.5% vs. 8.8%, HR 0.40, p  0.0001) and
ajor bleeding 48 h after the PCI (1.6% vs. 3.8%, HR 0.42,
 0.0001) (Fig. 3). When PCI was performed after 6 h
rom the last subcutaneous enoxaparin dose and UFH was
dded in the enoxaparin group (but not the fondaparinux
roup), abrupt/threatened abrupt closure was reduced (6.6%
ondaparinux alone vs. 4.3% UFH added to enoxaparin, RR
.40, p  0.048) (Fig. 3). The addition of UFH to the
noxaparin group 6 h after the last subcutaneous enoxaparin
njection lowered the rate of abrupt/threatened abrupt closure
ompared with those undergoing PCI with enoxaparin alone
4.3% UFH added to enoxaparin vs. 6.2% enoxaparin alone,
R 0.70, p  0.026) (Fig. 3). Importantly, the use of UFH
t least 6 h after the last enoxaparin subcutaneous injection
id not increase the risk of major bleeding in the enoxaparin
roup (3.8% enoxaparin alone vs. 3.4% UFH added to
noxaparin at least 6 h after the last subcutaneous dose)
Fig. 3).
With regard to catheter thrombus, there were a total of 8
ases reported with enoxaparin, 6 (0.4%) of which occurred
hen PCI was performed using enoxaparin alone and 2
0.16%) of which occurred when protocol-mandated UFH
as used (in 1 of these patients, PCI was performed with
FH before any study drug was given).
FFECT OF OPEN-LABEL UFH. After the OASIS-5 protocol
mendment, open-label UFH was permitted at the discre-
ion of the investigator and information regarding its use
as collected routinely in the final 1,758 patients undergo-
ng PCI. Additional open-label UFH before PCI was given
n 75 patients randomized to fondaparinux and 80 patients
andomized to enoxaparin. The mean dose of UFH used in
he fondaparinux group was 47 IU/kg. Catheter thrombus
ccurred in 10 fondaparinux-treated patients after the pro-
ocol amendment; 9 events occurred when no UFH was
iven before PCI (Table 5) and the remaining 1 case
ccurred in a patient who received a very low dose of
pen-label UFH (570 IU or 5 IU/kg). Importantly, major
leeding was not increased with use of open-label UFH in
he fondaparinux group (1.3% with open-label UFH vs.
.3% with no open-label UFH) (Table 5).
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October 30, 2007:1742–51 The OASIS-5 PCI Substudyleeding in relation to use of GP IIb/IIIa inhibitors and
retreatment with clopidogrel. Figure 4 shows bleeding
ates at day 30 in the enoxaparin and the fondaparinux
roups according to the concomitant use of GP IIb/IIIa
nhibitors and pretreatment with clopidogrel at least 6 h
efore PCI. There was a significant reduction in bleeding
Short-Term and Long-Term Major Adverse Clinic
Table 2 Short-Term and Long-Term Major Ad
Outcome
Fondaparinux
(n  3,105) (
At 9 days
Death, MI, or stroke 197 (6.3)
Death 37 (1.2)
MI 160 (5.2)
Stroke 12 (0.4)
Major bleeding 73 (2.4)
TIMI major bleeding 19 (0.6)
Minor bleeding 51 (1.6)
Total bleeding 121 (3.9)
Death, MI, stroke, major
bleeding
255 (8.2)
At 30 days
Death, MI, or stroke 229 (7.4)
Death 62 (2.0)
MI 177 (5.7)
Stroke 17 (0.6)
Major bleeding 88 (2.9)
TIMI major bleeding 25 (0.8)
Minor bleeding 53 (1.7)
Total bleeding 136 (4.4)
Death, MI, stroke, major
bleeding
296 (9.5)
At 6 months
Death, MI, or stroke 312 (10.1)
Death 99 (3.2)
MI 230 (7.5)
Stroke 25 (0.8)
Major bleeding 104 (3.4)
TIMI major bleeding 28 (0.9)
Minor bleeding 56 (1.8)
Total bleeding 155 (5.0)
Death, MI, stroke, major
bleeding
390 (12.7)
CI  confidence interval; MI  myocardial infarction; TIMI  Thrombo
ajor Bleeding in PCI Patientscc ding to the Day After Randomization
Table 3 Major Bleeding in PCI PatientsAccording to the Day After Randomization
Days After
Randomization
Fondaparinux
(n  3,105)
Enoxaparin
(n  3,072)
Relative
Risk p Value
Same day 0.2 0.5 0.35 0.037
1 0.7 1.7 0.40 0.001
2 1.1 2.8 0.40 0.001
3 1.4 3.6 0.40 0.001
4 1.7 4.0 0.42 0.001
5 1.8 4.3 0.42 0.001
6 2.0 4.7 0.42 0.001
7 2.2 5.0 0.43 0.001s
8 2.4 5.0 0.45 0.001ith fondaparinux irrespective of whether GP IIb/IIIa
nhibitors or clopidogrel was used. The distribution of
atheter thrombus in patients pretreated with clopidogrel, a
P IIb/IIIa inhibitor, or neither was similar in both
reatment groups, suggesting that antiplatelet therapy does
ot guard against this phenomenon.
iscussion
he results of the current analysis provide clear evidence
hat upstream therapy with fondaparinux in ACS patients
argeted for early PCI was superior to enoxaparin in
educing major bleeding by one-half while maintaining
imilar efficacy, which resulted in superior net clinical
enefit. The reduction in bleeding in ACS patients under-
oing PCI who were treated with fondaparinux was similar
o the reduction in bleeding observed with fondaparinux in
atients not undergoing PCI in the main OASIS-5 trial (9).
he reduction in bleeding complications was evident irre-
nts in PCI Patients
Clinical Events in PCI Patients
parin
,072) Hazard Ratio (95% CI) p Value
.2) 1.03 (0.84–1.25) 0.79
.2) 0.96 (0.61–1.52) 0.87
.0) 1.03 (0.82–1.28) 0.80
.4) 0.91 (0.42–2.00) 0.82
.1) 0.46 (0.35–0.61) 0.00001
.4) 0.43 (0.25–0.73 0.0019
.5) 0.36 (0.26–0.50) 0.00001
.4) 0.40 (0.33–0.50) 0.00001
0.4) 0.78 (0.67–0.93) 0.004
.4) 1.00 (0.83–1.20) 0.99
.1) 0.94 (0.67–1.34) 0.74
.5) 1.04 (0.84–1.29) 0.69
.7) 0.76 (0.41–1.44) 0.40
.4) 0.52 (0.40–0.67) 0.00001
.5) 0.54 (0.33–0.87) 0.012
.5) 0.37 (0.27–0.51) 0.00001
.8) 0.44 (0.36–0.53) 0.00001
1.8) 0.80 (0.69–0.93)
0.2) 0.99 (0.85–1.16) 0.95
.5) 0.92 (0.70–1.20) 0.53
.9) 1.09 (0.90–1.31) 0.38
.2) 0.71 (0.42–1.18) 0.18
.3) 0.53 (0.42–0.68) 0.00001
.7) 0.52 (0.33–0.82) 0.0052
.6) 0.39 (0.28–0.53) 0.00001
0.7) 0.46 (0.38–0.55) 0.00001
4.8) 0.84 (0.74–0.96) 0.013
Myocardial Infarction.al Eve
verse
Enoxa
n  3
190 (6
38 (1
154 (5
13 (0
155 (5
44 (1
138 (4
289 (9
318 (1
227 (7
65 (2
168 (5
22 (0
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The OASIS-5 PCI Substudy October 30, 2007:1742–51r pretreatment with a thienopyridine. Major bleeding was
ignificantly reduced by 65% with fondaparinux as early as
he end of the day of randomization and by 60% by the end
f the first day after randomization. These data show that,
n the context of an aggressive early invasive strategy in
hich relatively short durations of antithrombotic treatment
re administered, fondaparinux has substantial safety advan-
ages over enoxaparin. Thus, the net efficacy–safety balance
avors the use of upstream fondaparinux over enoxaparin in
atients with ACS undergoing PCI, including those pa-
ients undergoing early PCI.
Patients in the OASIS-5 study who underwent PCI
ore than 6 h after the last study drug administration
eceived additional intravenous fondaparinux if they were
Clinical Outcomes at Day 9 in PatientsUndergoing Early PCI (Within 24 h of Randomiza
Table 4 Clinical Outcomes at Day 9 in PatieUndergoing Early PCI (Within 24 h
Outcome
Fondaparinux
(n  1,414)
Death, MI, or stroke 75 (5.3)
Death 19 (1.3)
MI 53 (3.8)
Stroke 6 (0.4)
Major bleeding 33 (2.3)
Minor bleeding 30 (2.1)
Total bleeding 62 (4.4)
Death, MI, stroke, major bleeding 103 (7.3)
Abbreviations as in Table 2.
Figure 3 Major Bleeding and Angiographic Complications
Major bleeding 48 h after PCI and angiographic complications, according to
use of protocol-specified UFH in the enoxaparin group. If PCI was performed
within 6 h of the last subcutaneous enoxaparin dose, no additional UFH was
given. If PCI was performed after 6 h from the last subcutaneous enoxaparin
dose, supplemental UFH was administered for the PCI. Major bleeding was
reduced with fondaparinux irrespective of whether UFH was used in the
enoxaparin group. Angiographic complications were reduced when UFH was
used for the PCI procedure compared with either fondaparinux alone or with
enoxaparin alone. CI  confidence interval; RR  relative risk; other abbrevia-
tions as in Figure 1.sandomized to fondaparinux, but received UFH if they
ere randomized to enoxaparin. The UFH rather than
ntravenous enoxaparin was used in the latter case for 3
easons. First, enoxaparin is not approved for use by
egulatory agencies in patients undergoing PCI. Second,
he American College of Cardiology/American Heart
ssociation guidelines (11) and the European Society of
ardiology guidelines (12) recommend UFH as the
nticoagulant of choice in patients undergoing PCI.
hird, there were limited randomized data to support the
se of enoxaparin during PCI.
In the SYNERGY (Superior Yield of the New Strategy
f Enoxaparin, Revascularization, and Glycoprotein Inhib-
tors) trial (13), crossover from enoxaparin to UFH was
ssociated with higher bleeding complications. An adverse
ffect of crossover was not observed in the OASIS-5 trial
mong patients receiving protocol-mandated heparin at the
ime of PCI. Because the SYNERGY study was an open-
abel trial, the decision to cross over treatment from low-
olecular-weight heparin to UFH may have been prompted
y the development of a complication that resulted in a
igher incidence of bleeding. The OASIS-5 study was a
ouble-blind trial and, unlike the SYNERGY study, the use
f UFH in the enoxaparin group was defined according to a
et protocol. The addition of UFH to enoxaparin in over
,750 patients undergoing PCI in the OASIS-5 trial caused
o increase in bleeding complications, but had the advan-
age of preventing angiographic complications and catheter
hrombus in those patients randomized to the enoxaparin
roup. The lack of increased bleeding with UFH was likely
itigated by the minimum 6-h time delay between the last
ubcutaneous injection of enoxaparin and the administra-
ion of UFH for the PCI procedure.
Traditionally, UFH (which is predominantly a factor
Ia inhibitor with some factor Xa inhibitory capacity) has
een the anticoagulant used during PCI. The true rates of
atheter thrombus with UFH are unknown, but are likely
o be very low. More recently, low-molecular-weight
eparins, including enoxaparin and dalteparin, have been
valuated in randomized trials of PCI. The rates of
atheter thrombus reported with both of these agents are
ndomization)
Enoxaparin
(n  1,420)
Hazard Ratio
(95% CI) p Value
77 (5.4) 0.98 (0.71–1.34) 0.89
19 (1.3) 1.01 (0.53–1.90) 0.98
55 (3.9) 0.97 (0.66–1.41) 0.86
8 (0.6) 0.76 (0.23–2.18) 0.60
69 (4.9) 0.48 (0.31–0.72) 0.0005
78 (5.5) 0.38 (0.25–0.58) 0.00001
144 (10.2) 0.42 (0.31–0.57) 0.00001
135 (9.5) 0.76 (0.59–0.98) 0.035tion)
nts
of Raubstantially higher than those observed with UFH
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October 30, 2007:1742–51 The OASIS-5 PCI Substudy14 –16). In a recent trial evaluating enoxaparin in ST-
egment elevation MI patients targeted for primary PCI,
here were 3 cases of catheter thrombus of only 36
atients treated (12%), prompting a protocol amendment
14). In the OASIS-5 trial, catheter thrombus occurred
CI-Related Angiographic and Clinical Outcomes According tose of Open-Label UFH Given in the Catheterization Laboratory Bef
Table 5 PCI-Related Angiographic and Clinical Outcomes AccoUse of Open-Label UFH Given in the Catheterization La
No UFH Before P
Fonda (%) Enox (%) H
Number randomized 793 810
Mean dose of open-label UFH (IU/kg) — —
Median dose of open-label UFH (IU/kg) — —
At 30 days
Death/MI/stroke/major bleed 80 (10.1) 90 (11.1)
Death/MI/stroke 57 (7.2) 60 (7.4)
Major bleed 26 (3.3) 35 (4.3)
At study end
Death/MI/stroke/major bleed 101 (13.2) 109 (13.6)
Death/MI/stroke 77 (10.1) 78 (9.8)
Major bleed 28 (3.6) 41 (5.1)
Angiographic variables
Abrupt closure 15 (1.9) 13 (1.6)
Threatened abrupt closure 31 (3.9) 38 (4.7)
Catheter thrombus 9 (1.1) 4 (0.5)
Vascular access site complication 22 (2.8) 56 (6.9)
Pseudoaneurysm 6 (0.8) 8 (1.0)
Large hematoma 7 (0.9) 29 (3.6)
This 1 patient received a suboptimal dose of UFH (only 570 IU or 5 IU/kg) before PCI, compared
Enox  enoxaparin; Fonda  fondaparinux; UFH  unfractionated heparin; other abbreviations
Figure 4 Major Bleeding With Concurrent Use of GP IIb/IIIa
Antagonists and Pretreatment With Clopidogrel
Major bleeding in relation to concurrent use of glycoprotein (GP) IIb/IIIa antago-
nists and clopidogrel pretreatment at least 6 h before percutaneous coronary
intervention (PCI). Major bleeding was significantly reduced with fondaparinux
(yellow) compared with enoxaparin (red) with or without concurrent use of
these antiplatelet agents. GP IIb/IIIa ()  GP IIb/IIIa inhibitor used before/
during PCI; GP IIb/IIIa ()  GP IIb/IIIa inhibitor not used before/during PCI;
clopidogrel ()  clopidogrel given at least 6 h before PCI; clopidogrel () 
clopidogrel not given at least 6 h before PCI. CI  confidence interval; HR 
hazard ratio.gn1% of patients overall. Regardless of treatment, patients
ndergoing PCI who had catheter-related thrombus expe-
ienced significantly higher rates of ischemic events, includ-
ng death, MI, or stroke, whereas patients who experienced
ajor bleeding had a lower rate of these same events.
espite there being a higher proportion of catheter throm-
us in the fondaparinux group, the rates of death, MI, or
troke in the fondaparinux and the enoxaparin groups were
ot different. It is possible that any excess ischemic events
aused by catheter thrombus were balanced by a lower rate
f these events secondary to reduced bleeding. This suggests
hat if catheter thrombus could be prevented (for example by
sing UFH at the time of PCI), a benefit of fondaparinux on
ate ischemic events and mortality might be apparent, as it was
n the overall OASIS-5 trial (9). Certainly, the 8% lower
ortality at 6 months observed in the fondaparinux group
ndergoing PCI is consistent with the 17% reduction observed
n the overall trial, albeit with wide confidence intervals,
ecause it a subgroup involving about one-third of the total
ASIS-5 trial sample size.
The higher rate of catheter thrombosis among patients
reated with fondaparinux compared with enoxaparin might
e explained, in part, by the additional use of UFH in about
alf of the enoxaparin patients, which may have protected
his group against catheter thrombus. Other potential ex-
lanations are the differences in intensity of anticoagulation
nd increased contact pathway activation of the coagulation
ystem in patients treated with a selective factor Xa inhib-
tor. When either protocol-mandated UFH (in the
noxaparin group) or open-label UFH (in the fondaparinux
CI
to
ory Before PCI
UFH Before PCI
Ratio (95% CI) Fonda (%) Enox (%) Hazard Ratio (95% CI)
— 75 80 —
— 47 37 —
— 33 30 —
(0.67–1.22) 4 (5.3) 9 (11.2) 0.45 (0.14–1.47)
(0.68–1.40) 3 (4.0) 5 (6.3) 0.62 (0.15–2.61)
(0.45–1.25) 1 (1.3) 5 (6.2) 0.21 (0.02–1.79)
(0.72–1.24) 5 (6.7) 13 (18.6) 0.38 (0.14–1.07)
(0.74–1.39) 3 (4.0) 6 (8.1) 0.52 (0.13–2.06)
(0.24–0.79) 2 (2.7) 9 (13.5) 0.22 (0.05–1.03)
(0.56–2.5) 1 (1.3) 0 —
(0.52–1.32) 4 (5.3) 2 (2.5) 2.13 (0.40–11.3)
(0.71–7.4) 1 (1.3)* 0 —
(0.25–0.65) 1 (1.3) 5 (6.3) 0.21 (0.03–1.8)
(0.27–2.2) 0 0 —
(0.11–0.56) 0 4 (5.0) —
e mean UFH dose of 3,561 IU or 47 IU/kg in the fondaparinux group.
ables 1 and 2.ore P
rding
borat
CI
azard
0.90
0.97
0.75
0.94
1.02
0.69
1.18
0.83
2.30
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0.77
0.25roup) were used, catheter thrombosis was almost com-
p
t
t
p
p
u
c
o
i
t
v
a
t
g
f
C
A
I
s
u
s
t
f
p
P
b
I
b
f
m
t
t
u
P
s
n
P
s
l
w
t
a
t
w
e
f
b
t
n
O
P
u
f
w
c
p
e
C
F
P
m
r
t
e
A
t
a
w
t
a
R
I
D
H
R
1
1750 Mehta et al. JACC Vol. 50, No. 18, 2007
The OASIS-5 PCI Substudy October 30, 2007:1742–51letely eliminated, as might be expected. Therefore, al-
hough upstream fondaparinux is superior to enoxaparin in
erms of net clinical benefit, we recommend that in fonda-
arinux-treated patients, UFH rather than intravenous fonda-
arinux be used as adjunctive therapy at the time of PCI. The
se of UFH for PCI is familiar to interventional cardiologists,
an be monitored using the ACT, and to our knowledge, no
ther antithrombin evaluated to date has proven to be superior
n terms of efficacy to UFH for PCI.
Importantly, the protection provided against catheter
hrombus and angiographic complications by adding con-
entional doses of UFH to fondaparinux or enoxaparin (6 h
fter the subcutaneous dose of the latter) did not increase
he risk of major bleeding in either randomized treatment
roup, thus ensuring that the substantial benefit of upstream
ondaparinux in reducing bleeding was maintained. The
RUSADE (Can Rapid Risk Stratification of Unstable
ngina Patients Suppress Adverse Outcomes With Early
mplementation of the ACC/AHA Guidelines) registry
howed that about 30% of ACS patients in the U.S. will
ndergo early PCI (5). Fondaparinux might be used up-
tream in these patients, with UFH added at PCI, whereas
hose patients not undergoing PCI can be treated with
ondaparinux alone.
Bivalirudin was not used in the OASIS-5 trial, but
revious randomized studies in patients undergoing elective
CI (17) or urgent PCI (18) have shown lower rates of
leeding with bivalirudin compared with UFH and a GP
Ib/IIIa inhibitor. It follows logically that the use of
ivalirudin during PCI in patients treated upstream with
ondaparinux might be a very attractive option for the
anagement of ACS patients. Such a strategy should be
ested in future randomized controlled trials.
A limitation of our analysis is that the randomized
reatments themselves may have influenced which patients
nderwent PCI. However, the types of patients undergoing
CI and the number and timing of PCI procedures was
imilar in the 2 randomized treatment groups. Secondly, the
umber of patients who received open-label UFH before
CI in the OASIS-5 trial was modest. However, UFH is
tandard therapy for PCI (11,12) and is associated with a
ow rate of catheter thrombus. Thus, the key issue is not
hether UFH can prevent catheter thrombus in patients
reated with upstream fondaparinux, but rather whether the
ddition of UFH to fondaparinux is safe. The OASIS-5
rial data suggest that the substantial reduction in bleeding
ith fondaparinux compared with enoxaparin is maintained
ven when open-label UFH is used on top of upstream
ondaparinux (19).
In the OASIS-6 trial, fondaparinux did not increase
leeding compared with placebo in stratum 1, but never-
heless reduced mortality and recurrent MI (20). There were
o cases of catheter thrombus and no increase in bleeding in
ASIS-6 among the 231 patients undergoing nonprimary
CI who received protocol-mandated UFH on top of
pstream fondaparinux (including those undergoing rescue,acilitated, or early routine PCI) (20). This is consistent
ith the results of the OASIS-5 study and supports the
onclusion that the use of UFH for the PCI procedure in
atients treated upstream with fondaparinux is both safe and
ffective.
onclusions
or upstream management of ACS patients undergoing
CI, fondaparinux is superior to enoxaparin in preventing
ajor bleeding while maintaining similar efficacy, thereby
esulting in superior net clinical benefit. Catheter-related
hrombosis occurs rarely when either fondaparinux or
noxaparin is used as the only anticoagulant during PCI.
dding UFH during PCI reduces the risk of catheter
hrombus, without increasing bleeding. Thus, a tailored
pproach of using fondaparinux in a broad range of patients
ith ACS as initial upstream therapy, followed by targeted
herapy with UFH in those who require a PCI procedure, is
n attractive strategy for the management of ACS.
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